Fisetin for Skin: Antioxidant, Senolytic, and Topical

Does fisetin actually help your skin? What the evidence shows

Fisetin has a growing preclinical skin literature, including UVB photoprotection, collagen-related changes, dermal senescence biology and a 2026 diabetic-wound model. No published human trial has yet tested oral or topical fisetin for a skin outcome, so clinical claims remain unproven.

Topical and oral fisetin are different interventions with different evidence bases, which this article treats separately. For the full clinical context, see our complete clinician's guide and our dedicated senolytic article.

What does the mouse UVB evidence actually show?

Wu 2017 — the main UVB photoprotection study

The most consequential preclinical skin paper on fisetin is Wu and colleagues' 2017 study in hairless mice [1]. Mice were exposed to chronic UVB irradiation with or without topical fisetin. Three findings anchor the paper: reduced erythema and epidermal hyperplasia, reduced wrinkle formation with preserved dermal collagen (fisetin suppressed the matrix metalloproteinases that UVB upregulates to degrade collagen), and activation of the Nrf2 antioxidant pathway, which raises the skin's own antioxidant defences.

Pal 2015 — a second UVB mouse model, different pathway

A separate hairless-mouse UVB study found that topical fisetin reduced cutaneous inflammation partly by inhibiting the PI3K/AKT/NF-kB signalling pathway [2]. This adds a second, independent mechanistic route — alongside Wu's Nrf2 finding — for how topical fisetin might reduce UVB-driven skin inflammation, though it's a different mouse model and doesn't establish whether the two mechanisms act together in the same tissue.

Together, these two mouse studies build a mechanistically coherent preclinical case for topical fisetin as a photoprotective agent. Neither has been followed by a human trial.

Does fisetin clear senescent skin cells?

Beyond direct photoprotection, fisetin's senolytic identity is relevant to skin because dermal fibroblasts — the cells that produce collagen and elastin — accumulate senescence with age, particularly in chronically sun-exposed skin. Senescent fibroblasts secrete SASP factors that break down surrounding collagen and impair nearby healthy fibroblast function.

Yousefzadeh and colleagues showed senolytic activity in selected experimental cell systems and animal models [3]. That supports the broader senotherapeutic rationale, but it does not establish systemic senescent-cell clearance in humans.

The 2026 topical diabetic-wound experiment

Numani and colleagues (February 2026) randomized 24 diabetic mice to topical fisetin or vehicle, with 12 animals per group and treatment on three consecutive days each week [6]. Fisetin-treated wounds showed a higher healthy-dermis-to-granulation ratio at day 7 and less dermal fibrosis at day 21. Some inflammatory markers and p16-positive cells decreased, while p21-positive cells increased at day 7.

Importantly, gross wound-area measurements did not show significantly faster wound closure. The mixed senescence-marker pattern supports describing fisetin as a modulator of wound biology in this mouse model—not as a proven treatment for human diabetic wounds, skin ageing or wrinkles.

Oral vs topical fisetin for skin — different interventions, different biology

Oral fisetin for skin

Oral fisetin has low systemic exposure in human pharmacokinetic research [5]. How much parent fisetin or active metabolite reaches human skin after supplementation has not been established, and plasma concentrations should not be converted directly into a dermal "senolytic threshold." No oral human trial has shown a skin benefit.

Topical fisetin for skin

Topical delivery avoids gastrointestinal absorption, but actual penetration into human dermal tissue and comparative clinical efficacy remain unmeasured. Mouse studies have used topical delivery, including the 2026 diabetic-wound study [6]. However, fisetin is poorly water-soluble, and skin penetration depends on concentration, vehicle and formulation. No standardized topical fisetin product, concentration or application schedule has been validated in a controlled human trial.

What about formulated (liposomal) fisetin?

A separate line of research has tested liposome-encapsulated fisetin's effect on the senescence-associated secretory phenotype (SASP) — the inflammatory signalling senescent cells produce. That study found liposomal fisetin suppressed SASP in senescent lung fibroblast and lung adenocarcinoma cell lines, a senomorphic (SASP-quieting) rather than senolytic (cell-killing) effect. It did not test dermal fibroblasts or skin tissue specifically. Whether the same senomorphic effect would hold in skin cells, and whether a liposomal topical formulation would out-perform simpler oil-based vehicles for skin penetration, hasn't been tested. See our liposomal fisetin article for the broader senolytic-vs-senomorphic story.

What should you actually do?

A high-quality broad-spectrum sunscreen is the load-bearing intervention for skin ageing — no supplement or topical antioxidant substitutes for adequate sun protection. Everything below is a plausible adjunct, not a replacement.

Topical fisetin remains experimental for cosmetic or wound-healing outcomes. Product concentration and vehicle matter pharmacologically, but no human trial has established an effective concentration, preferred vehicle or clinical benefit.

Oral fisetin has not been shown to improve any skin outcome in a controlled human trial. No validated systemic or dermal exposure threshold exists, so potential cosmetic effects should not be treated as expected benefits.

Dietary strawberries deliver small quantities of fisetin alongside vitamin C and other antioxidants relevant to skin health, as part of a general polyphenol-rich diet.

Further reading: the separate evidence for hair-growth and pigmentation; the uncertainties surrounding oral absorption and tissue exposure; the separate human inflammation and joint-outcome evidence. Cell and mouse findings do not demonstrate topical efficacy in people.

What we still don't know

Whether topical fisetin produces a measurable clinical benefit on wrinkles, photodamage, or dermal thickness in humans — no RCT has tested this.

Whether oral fisetin at any supplement dose meaningfully reduces dermal senescent-cell burden in humans — plasma-to-skin distribution hasn't been measured.

The optimal topical concentration, vehicle, and application frequency for fisetin — no standardised product has been validated.

Whether a liposomal or nanoemulsion topical formulation would outperform simpler oil-based vehicles for skin penetration specifically — the existing liposomal fisetin data are from lung cell lines, not skin.

How fisetin interacts with retinoids, vitamin C, or peptide serums in a real skincare routine — untested.

Bottom line

Fisetin has meaningful preclinical skin evidence, but the effects are model-specific. UVB mouse studies support photoprotection-related mechanisms, while a 2026 topical diabetic-wound study changed senescence, inflammation and fibrosis measures without significantly accelerating wound closure [6]. No human trial has established a skin benefit from oral or topical fisetin. Broad-spectrum sun protection remains the evidence-based foundation for preventing photoageing; fisetin should be treated as experimental rather than a validated anti-ageing skincare intervention.